KOSDAQBiotech & Pharma308080

ViGenCell

₩4,165▼ 5.23%2026-11-18 close
Market Cap
₩85.4B
Turnover
₩1.1B
Volume
280K
Shares out.
20.5M
PER
—
PBR
2.5×
EPS
-₩657
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Loss-Making ViGenCell Hinges on VT-EBV-N Approval Path

ViGenCell has posted losses for five straight quarters through the third quarter of 2026, so its equity story depends on whether VT-EBV-N secures conditional approval or a licensing deal.

  1. 1

    Revenue fell to KRW 22.67 million in 2025, a 91.9% decline from the prior year, and the operating loss widened to KRW 17.1 billion. The company has recorded losses for four straight years from 2022 through 2025.

  2. 2

    In the Phase 2 final results, the two-year disease-free survival rate was 95.0% in the treatment arm versus 77.58% in the control arm. The secondary endpoint, overall survival, did not reach statistical significance (p=0.058).

  3. 3

    The Phase 1 trial of the AML candidate VT-Tri(1)-A was terminated early in February 2026, continuing a pipeline pruning that began with VM-GD. Resources are now concentrated on VT-EBV-N and the iPSC-derived CAR-NK program.

  4. 4

    Press reports cite a plan to pursue conditional product approval in the second half of 2026 and a domestic launch in the first half of 2027. Licensing talks with Chinese and global pharmaceutical companies are reported to be ongoing.

  5. 5

    Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 13.4 billion, so earnings-based multiples cannot be calculated. Total equity of KRW 43.7 billion is entirely attributable to controlling shareholders.

02

Business structure

ViGenCell is a biopharmaceutical company developing immune cell therapies. Its lead pipeline, VT-EBV-N (also coded VC-101), is an autologous T-cell therapy aimed at EBV-positive NK/T-cell lymphoma, a rare hematologic cancer with no established standard treatment.

The company has said that roughly 75% of patients relapse within two years. Follow-on candidates include VC-302, an iPSC-derived, GD2-targeted allogeneic CAR-NK therapy for glioblastoma developed with a co-development partner, and VC-420 for hepatocellular carcinoma.

ViGenCell highlights its in-house GMP facility, the V-Cell Center, together with a network of medical institutions, as covering development through manufacturing and supply. Revenue does not yet come from sales of approved drugs.

Press reports put first-half 2026 standalone revenue at KRW 900 million, of which 98% was product sales and 2% service revenue. Service revenue from contract manufacturing and contract development forms part of the external revenue base.

The business model centers on out-licensing in-house immune cell therapies and gaining product approval for key pipeline assets. A June 2026 report said VT-EBV-N was also selected as the first treatment under Korea's advanced regenerative medicine system. Because NK/T-cell lymphoma has no standard therapy, direct competitive comparisons are limited.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8,001,000-₩2.4B−30405.0%
2025Q4₩14,051,000-₩6.3B−45073.8%
2026Q1₩300M-₩2.8B−862.5%
2026Q2₩600M-₩2.5B−444.0%
2026Q3₩600M-₩2.6B−464.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩0-₩18.2B-₩17.4B—−19.4%10.9%
2023₩0-₩20.1B-₩17.9B—−25.0%13.4%
2024₩300M-₩15.3B-₩14.1B−5495.9%−24.2%16.1%
2025₩22,674,300-₩17.1B-₩16.3B−75453.1%−37.3%24.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a DART basis, revenue was KRW 279 million in 2024 and KRW 22.67 million in 2025, a 91.9% decline; no 2023 revenue figure is reported. Even as the revenue base nearly disappeared in 2025, the operating loss widened to KRW 17.1 billion from KRW 15.3 billion in 2024.

The operating margin deteriorated from -5,495.9% in 2024 to -75,453.1% in 2025, largely because the revenue denominator shrank. The operating loss was KRW 18.2 billion in 2022, KRW 20.1 billion in 2023, KRW 15.3 billion in 2024 and KRW 17.1 billion in 2025, marking losses in four straight years from 2022 through 2025.

Net loss attributable to controlling shareholders was KRW 17.4 billion in 2022, KRW 17.9 billion in 2023, KRW 14.1 billion in 2024 and KRW 16.3 billion in 2025, and the total net loss including non-controlling interests followed the same pattern.

Operating cash flow was -KRW 11.1 billion in 2022, -KRW 15.3 billion in 2023, -KRW 10.9 billion in 2024 and -KRW 13.8 billion in 2025. The debt-to-equity ratio (total liabilities divided by total equity) rose from 10.9% in 2022 to 24.1% in 2025, when total liabilities were KRW 10.6 billion.

Quarterly revenue went from KRW 8 million in Q3 2025 to KRW 14.05 million in Q4 2025, KRW 329 million in Q1 2026, KRW 571 million in Q2 2026 and KRW 566 million in Q3 2026. Operating losses widened to KRW 6.33 billion in Q4 2025 and then ran at KRW 2.84 billion, KRW 2.54 billion and KRW 2.63 billion in Q1 to Q3 2026.

Revenue growth has been large in percentage terms but too small in absolute size to offset costs. A 2021 securities registration statement had projected operating profit for 2025, against a reported operating loss of KRW 17.1 billion. Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 13.4 billion.

05

Industry analysis

NK/T-cell lymphoma is a rare hematologic cancer without an established standard therapy, and it is described as having high relapse rates and substantial unmet need.

The company cites a patient pool in China of roughly 30 times Korea's and says that expanding into EBV-associated solid tumors could create more than 60,000 new patients a year. These are company-cited estimates, so they cannot be read directly as market size.

In Korea, only one anticancer drug, Yuhan's lazertinib approved in 2021, is cited as having received conditional approval based on Phase 2 data alone.

Analysts note that lazertinib had no secondary-endpoint issue and ran a Phase 3 trial alongside its global licensing deal, which makes its situation different from VT-EBV-N. Whether Korea's advanced regenerative medicine system functions as a real treatment pathway is a key point of differentiation.

The company said that from September 2026 it began treating and enrolling patients under a treatment plan approved in Korea. In cell therapy, next-generation immune cell therapies such as CAR-T and CAR-NK are the main competitive axis.

ViGenCell positions itself on holding both autologous personalized and allogeneic off-the-shelf therapies. Commercial outcomes will depend on clinical results and whether approval and licensing deals are secured.

06

Outlook

The company said it planned to file for Advanced Biopharmaceutical designation for expedited review and for the Global Innovative Drug Fast-Track (GIFT) program during the first half of 2026. It also outlined a plan to pursue full conditional product approval in the second half of 2026.

Press reports say that if approval is granted, a domestic launch through a local commercial partner is expected in the first half of 2027. Because of the missed secondary endpoint, even experts say the likelihood of conditional approval is difficult to pin down.

On licensing, reports say talks with global big pharma and large Chinese pharmaceutical companies have continued since the company attended BIO-China 2026. Key negotiating points are the scope of development and manufacturing and the extent of additional clinical requirements.

Expansion indications mentioned include EBV-associated solid tumors such as nasopharyngeal cancer. The follow-on asset VC-302 is being developed with an IND filing targeted for 2027.

According to a BloterKorea report, the sales requirement waiver ends in 2026, so the company must achieve annual revenue of KRW 3 billion. Press reports also note that the sales-based listing exemption granted at its 2021 technology-growth listing is approaching its expiry. Both requirements can be checked in the 2026 annual report.

07

Valuation

PER
—
PBR
2.5×
ROE
-31.3%
EPS
-₩657
BPS
₩1,800
Dividend per share
₩0

Earnings-based multiples cannot be calculated because the last four quarters show net losses. On a net-asset basis, the share price sits in a premium range above book value, which suggests the market already reflects a substantial portion of the clinical and licensing potential.

Total equity of KRW 43.7 billion is entirely attributable to controlling shareholders, and total liabilities of KRW 10.6 billion are small relative to that base. No dividend income is currently paid, so shareholder value depends on share price movement and on cash flows after commercialization.

A 2021 securities registration statement projected operating profit for 2025, while the reported 2025 operating loss was KRW 17.1 billion. That gap shows the difference between projections and filed results.

The valuation debate centers on the conditional approval outcome and the terms of any licensing agreement, and until those are settled, interpretation is largely limited to comparing levels.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Primary endpoint success in Phase 2

The two-year disease-free survival rate was 95.0% in the treatment arm versus 77.58% in the control arm, reaching statistical significance on the primary endpoint. Press reports say events occurred in 32% of control patients compared with one patient (4.76%) in the treatment arm. The company said VT-EBV-N was selected for oral presentations at both ASCO and EHA.

Multiple approval pathways

The company planned to file for expedited designations, including Advanced Biopharmaceutical status and GIFT, during the first half of 2026. A June 2026 report said VT-EBV-N was selected as the first treatment under Korea's advanced regenerative medicine system. The company said patient treatment and enrollment under that system have been ongoing since September 2026.

Global licensing demand

The company cites a patient pool in China roughly 30 times Korea's as the basis for licensing discussions. Reports say meetings with global big pharma and large Chinese pharmaceutical companies took place after BIO-China 2026. The company has said it will concentrate resources on VT-EBV-N and the iPSC-derived CAR-NK program.

09

Bear factors

Secondary endpoint and conditional approval uncertainty

Overall survival reached a p-value of 0.058, short of the conventional 0.05 threshold, in a trial of only 48 patients. Experts say the secondary-endpoint miss should not be called a failure, yet they generally view the conditional approval outcome as hard to predict. The share price fell 23.95% on the day the final study report was disclosed.

Persistent losses and a revenue gap

The company recorded operating losses for four straight years from 2022 through 2025, and operating cash outflows occurred in every one of those years. Revenue fell to KRW 22.67 million in 2025, and the operating margin deteriorated to -75,453.1%.

Compared with the 2025 profit projected in the 2021 registration statement, the gap between forecast and reported results is wide.

Single-asset dependence and pipeline pruning

The VM-GD Phase 1/2a trial was terminated early at the end of 2024, and the VT-Tri(1)-A Phase 1 trial was terminated early in February 2026. With the remaining core asset concentrated in VT-EBV-N alone, any delay in approval or licensing leaves limited alternatives.

Having discontinued two programs, the company also faces uncertainty over how its follow-on assets will progress.

10

Risk factors

Regulatory risk

Because the secondary endpoint was missed, the Ministry of Food and Drug Safety's conditional approval decision is uncertain, and few anticancer drugs in Korea have won conditional approval on Phase 2 data alone.

If the scope of required additional trials expands, approval and launch could slip from the first-half 2027 target. The company has said it will consult extensively with regulators.

Financial risk

Operating losses have persisted for four years from 2022, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 13.4 billion. Analysts note that the KRW 3 billion annual revenue requirement and the expiring listing exemption make revenue generation urgent. If additional funding becomes necessary, dilution of existing shareholders cannot be ruled out.

Commercialization and partnering risk

The economics of any licensing deal depend on the scope of development and manufacturing, royalty terms and the burden of additional trials. If talks with Chinese and global partners run long, the timing of upfront payments will also slip. Division of roles with the domestic commercial partner and post-launch sales performance remain unproven.

11

What to watch next

  1. From December 2026

    Whether a conditional product approval application for VT-EBV-N has been filed and how Ministry of Food and Drug Safety review progresses. Any request for supplementary data would be the main variable for the first-half 2027 launch target.

  2. Late March 2027

    Filing of the 2026 annual report. Key checks are whether 2026 annual revenue reached the KRW 3 billion requirement and how the operating loss and operating cash flow turned out.

  3. Mid-May 2027

    The Q1 2027 quarterly report. The checkpoints are whether quarterly revenue continues the 2026 trend and whether the operating loss, which ran between KRW 2.5 billion and KRW 2.8 billion in 2026, begins to narrow.

  4. First half of 2027

    The target timing of the domestic launch of VT-EBV-N and whether a licensing agreement is signed. Upfront payment size, royalties and the scope of development and manufacturing will shape the revenue structure.

  5. During 2027

    The targeted IND filing for the VC-302 Phase 1 trial, an indicator of whether the allogeneic CAR-NK pipeline advances to its next stage.

12

Overall view

ViGenCell has recorded operating losses for five straight quarters through the third quarter of 2026, and reported revenue fell to KRW 22.67 million in 2025. The weight of the business rests on approval and licensing of the NK/T-cell lymphoma candidate VT-EBV-N.

The two-year disease-free survival rate was higher than in the control arm, and the company has been selected for consecutive oral presentations at ASCO and EHA. On the other hand, overall survival, the secondary endpoint, did not reach statistical significance, and the trial enrolled only 48 patients.

The pipeline has narrowed to a single core asset after the GvHD and AML programs were stopped. On the financial side, the company has posted four straight years of losses from 2022 through 2025 with operating cash outflows, and its debt-to-equity ratio rose to 24.1% in 2025.

The next checkpoints are the conditional approval filing and review outcome, annual revenue shown in the 2026 annual report, and whether a licensing agreement is signed.

Strengths and weaknesses coexist, so until approval results and deal terms are disclosed, the direction of the business value cannot be determined with confidence.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thebionews.net
  2. dailypharm.com
  3. hankyung.com
  4. thebionews.net
  5. m.news.nate.com
  6. news2day.co.kr
  7. view.asiae.co.kr
  8. m.news.nate.com
  9. pharm.edaily.co.kr
  10. thebionews.net
  11. m.news.nate.com
  12. edaily.co.kr
  13. pinpointnews.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. pharm.edaily.co.kr
  18. leadeconomy.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis